Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Duitse aandelen  /  BAYER AG

Ontvang nu dagelijks onze kooptips!

word abonnee

Duitse aandelen« Terug naar discussie overzicht

BAYER AG

1.223 Posts
Pagina: «« 1 ... 49 50 51 52 53 ... 62 »» | Laatste | Omlaag ↓
  1. forum rang 7 4finance 11 oktober 2021 10:33
    quote:

    stockholder schreef op 8 oktober 2021 16:35:

    Parkeren we de Round-up kwestie even dan hebben we met een gezond en winstgevend bedrijf te maken.
    Daarboven op komt nog de mooie dividend uitkering.
    Aandelen vasthouden. Zodra Round-Up kwestie is opgelost, schieten we omhoog.
    Zo is dat. Geduld hier. Er komt beslist weer een moment dat BAYER vanaf dit niveau fors hoger staat.
    Zelf heb ik onder in de 45 nog wat bijgekocht. Had er op dat moment niet erg veel vertrouwen in maar toch gedaan.
    Gelukkig is het niet naar de 40 gegaan. Het aandeel staat nu rond de 48 te slingeren.

    Kortom; hopen op betere tijden. Round-UP oplossen en een nieuwe CEO zal enorm helpen om de koers een heel stuk hoger te zetten.

  5. forum rang 7 LL 19 oktober 2021 17:05
    quote:

    4finance schreef op 19 oktober 2021 11:51:

    BAYER, kon vanmorgen de "verleiding" niet weerstaan om nog wat Bayer net onder de €46 bij te kopen.

    Alles hangt hier van afronding Round-up af.

    Great timing 4finance!

    Bayer: no guidance hit from hurricane, planting trends

    BERLIN, Oct 19 (Reuters) - Bayer sees no impact on its full-year guidance from customers' changing planting habits or a five-week shutdown at its main glyphosate production site in Louisiana after Hurricane Ida, the German life science group said on Tuesday. [nL1N2QI1SR]

    Bayer had to close the Louisiana factory after the hurricane slammed the Gulf Coast in late August, further complicating logistical and supply chain problems that had already tightened global supplies of fertilizers and chemicals.

    "We lost five weeks of production. This will, of course, involve some cost that will have an impact on sales, but nothing to any degree that would impact our full year guidance for this year," Liam Condon, president of Bayer's agricultural unit, told investors during an online event.

    Asked if rising production prices may push customers to shift to soy from corn, which is a cornerstone of Bayer's performance, Condon said he would see any changes as seasonal fluctuations rather than anything that could affect the unit's outlook.

    "Most farmers have a fixed rotation between corn and soybeans. They usually look at what they what they had in the past season and aim to rotate to keep the soil fertile," he said.

    Corn is a very profitable crop and rising fertilizer prices cause an increase in corn prices as well, he said, adding farmers rarely take final planting decisions before the spring as they depend heavily on the overall weather situation.

    (Reporting by Zuzanna Szymanska, editing by Emma Thomasson, Kirsten Donovan)

    ((zuzanna.szymanska@thomsonreuters.com;))
  7. forum rang 7 4finance 20 oktober 2021 09:47
    quote:

    KipCorn schreef op 19 oktober 2021 17:09:

    Heel goed, Bayer heeft wel potentie naar €70.

    Dat zou mooi zijn. Zit er nu gemiddeld in op €58. Heb dus nog en aardige inhaalslag te maken.
    De andere kant is wel dat ik al 3 jaren dividend heb gekregen. Al met al zit ik er rustig in.
    Bayer kan ook weer heel hard stijgen vanaf dit niveau.

  8. forum rang 7 LL 26 oktober 2021 15:44

    Tuesday - October 26, 2021
    Bayer to speed global development of vegetable seeds varieties at expanded R&D Center in Spain
    €5.1 million expansion will bring high quality seeds to worldwide markets faster, providing solutions for growers and meeting consumer demands / The seven-hectare global Product Design Center in San Nicolás includes state-of-the-art lab space for cell biology research and greenhouses for seed production

    Monheim/Germany, October 26, 2021 – Bayer signals its commitment to delivering high quality cucumber, melon, pepper and eggplant seeds faster to growers around the world with the announced expansion of its Vegetable Seeds R&D Product Design Center in San Nicolás, Spain. The San Nicolás site supports Bayer’s global vegetable seeds R&D pipeline for varieties sold to customers in more than 130 countries and territories under the Seminis® and De Ruiter® brands, both united under Vegetables by Bayer.

    “By using advanced breeding techniques that help speed up the time to market for new varieties, we’re helping growers respond to unexpected challenges of today and into the future,” said Inci Dannenberg, Head of Global Vegetable Seeds at Bayer. “Our customers and value chain partners can’t afford to wait around for solutions to new disease pressures, unpredictable weather patterns or rapidly changing market demands.”

    With the largest investment in research and development in the industry, Bayer began the €5.1 million expansion of the Product Design Center in September 2019. The expansion includes a multifunctional R&D facility for cell biology, laboratories, cell culture rooms, climate-controlled chambers, and plans to develop a high-tech greenhouse space. It also allows for a three-fold increase in capacity for innovative doubled haploid (DH) production methods.

    bron:
    media.bayer.com/baynews/baynews.nsf/i...
  9. forum rang 7 LL 29 oktober 2021 14:25
    Bayer wins EU patent extension for best-selling Xarelto drug

    BERLIN, Oct 29 (Reuters) - Bayer on Friday said the European Patent Office had maintained the company's patent for its best-selling stroke prevention pill Xarelto (rivaroxaban), extending the patent's expiry date by almost two years.

    Bayer said several drugmakers had opposed the drug's patent but the EU authority extended Bayer's intellectual property rights until January 2026.

    The decision will prevent almost all EU countries and certain non-EU states, such as the United Kingdom and Switzerland, from launching rivaroxaban, which is intended to be administered once a day, as a generic drug.

    "Bayer welcomes the positive decision strengthening the patent and will continue to vigorously defend its intellectual property," the German drugmaker said in a statement.

    Bayer's 2020 drugs business was shored up by strong prescription growth in Xarelto, which made 4.515 billion euros ($5.26 billion) in revenues and continued to grow in the first half of 2021.

    (Reporting by Riham Alkousaa; Editing by Nick Macfie)
  13. forum rang 7 LL 3 november 2021 15:24
    U.S. farm co-op CHS to pay members to enroll in Bayer carbon farming program

    Nov 3 (Reuters) - Agricultural seeds and chemicals supplier Bayer AG is expanding its carbon farming program to members of U.S. farm cooperative CHS Inc , boosting incentives for members to participate in the program, the companies said on Wednesday.

    The agreement will make it easier for CHS's 75,000 farmer-members to enroll in Bayer's Carbon Program, an early leader in the drive to encourage farmers to capture carbon by planting off-season crops, tilling the ground less and use fertilizer more efficiently.

    It also expands the program from 17 states to 21, the companies said.

    The Bayer Carbon Program pays growers up to $9 an acre for planting cover crops and reducing soil tillage. Farmers in the program log their practices on digital platforms to generate a carbon credit.

    Agricultural companies use the credits to offset the climate impact of other parts of their businesses or sell them to companies looking to reduce their own carbon footprints.

    It is the latest collaboration between large agricultural firms racing to sign up acres for carbon sequestration, or trapping atmosphere warming carbon underground, and environmental credit trading programs. [nL1N2Q91UU]

    Some farmers have embraced the carbon programs as a welcome new stream of revenue and a potentially powerful tool to combat climate change. Others have voiced suspicion that companies will collect farming data that will be used to sell them more products.

    CHS will pay its members an additional $3 an acre for enrolling in Bayer's program and purchasing certain products such as "enhanced-efficiency fertilizers." Payments will be distributed in the fourth quarter of 2022, CHS said.
  18. SanderK0 8 november 2021 11:34
    Ik verwacht dat de cijfers gaan meevallen. Er zou toch een keer licht in het einde van de tunnel moeten komen.
    Echter, dit aandeel zal pas echt pas in beweging komen als de roundup kwestie is beslecht. Tot die tijd zal het een grote smet zijn waar grotere beleggers zich niet aan willen branden.
  19. forum rang 7 LL 9 november 2021 07:17
    Monday - November 8, 2021
    The American Society of Nephrology (ASN)’s Kidney Week 2021:
    New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy

    Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study / Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with finerenone reduced the risk of cardiovascular events and of disease progression of CKD, underpinning the importance of timely intervention in patients with CKD and T2D / Data from prespecified pooled analysis FIDELITY of more than 13,000 patients from the Phase III studies FIGARO-DKD and FIDELIO-DKD underscore the potential benefit of finerenone across the disease spectrum, and irrespective of concomitant treatment with SGLT2 inhibitors in patients with CKD and T2D

    Berlin, November 8, 2021 – New data analyses of the comprehensive finerenone clinical trial program, including the pivotal Phase III studies FIGARO-DKD and FIDELIO-DKD and the pre-specified pooled analysis FIDELITY reinforce the renal and cardiovascular (CV) benefits of finerenone, the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist, in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Data from the analyses were presented at the American Society of Nephrology (ASN)’s Kidney Week 2021 in two oral presentations and two late-breaking posters.

    In the FIGARO-DKD study, presented at ESC Congress 2021 and published in the New England Journal of Medicine, the incidence of the first secondary endpoint, a composite of time to kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) = 40% from baseline over a period of at least four weeks, or renal death occurred in 350 (9.5%) patients in the finerenone arm and 395 (10.8%) patients in the placebo arm; this narrowly missed statistical significance (HR 0.87 [95% CI: 0.76-1.01]; p=0.0689) over a median duration of follow-up of 3.4 years. In the oral session presented at ASN’s Kidney week on an exploratory analysis of the FIGARO-DKD study data in patients with CKD stages 1–4 with moderate-to-severely elevated albuminuria, it was seen that finerenone reduced the risk for the =40% and =57% estimated glomerular filtration rate (eGFR) kidney composite outcomes, which was generally consistent with the benefit seen in FIDELIO-DKD. The effect of finerenone on the composite kidney outcomes was reflected by a 36% relative risk reduction of end-stage kidney disease (ESKD). ESKD occurred in 0.9% of finerenone versus 1.3% placebo recipients (HR=0.64; 95% CI 0.41-0.995; p=0.046).

    An analysis of the FIDELIO-DKD study, presented as a late-breaking poster, evaluated the association between urine albumin-to-creatinine ratio (UACR) change and CV and renal protection in patients with CKD and T2D. Compared to FIGARO-DKD, FIDELIO-DKD included more patients with advanced chronic kidney disease. The data demonstrate that finerenone reduced the risk of the CV composite outcome (time to CV death, non-fatal MI, nonfatal stroke or heart failure hospitalization) and the kidney composite outcome (time to kidney failure, sustained =40% decrease in eGFR =4 weeks from baseline, or renal death), early but also irrespective of a change in UACR from baseline to month four.

    “More needs to be done to slow the progression of chronic kidney disease (CKD) secondary to type 2 diabetes (T2D). It is the most common cause of end-stage kidney disease (ESKD) worldwide,” said Professor George L. Bakris, MD, Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, USA and principal investigator of the FIDELIO-DKD trial. “The results presented at ASN from FIDELIO-DKD and FIGARO-DKD, and specifically from the FIDELITY pooled analysis of these trials, clearly demonstrate the potential to improve outcomes in patients through timely detection and monitoring of the earliest signs of chronic kidney disease. Moreover, they underscore finerenone as a potential effective treatment option to improve cardiovascular and kidney outcomes across a broad range of patients, including those with early kidney damage and more advanced stages of CKD and T2D.”

    Results from FIDELITY, a prespecified pooled analysis of more than 13,000 patients from the Phase III studies FIGARO-DKD and FIDELIO-DKD, were presented as a late-breaking poster at Kidney Week 2021, further demonstrating the renal and CV benefits of finerenone across the spectrum of CKD severity in patients with T2D. The results show that finerenone consistently reduced the risk of the kidney composite outcome (time to kidney failure, sustained =57% decrease in eGFR from baseline, or renal death) by 23% (HR=0.77; 95% CI 0.67–0.88; p=0.0002), and the risk of ESKD by 20% (HR=0.80; 95% CI 0.64–0.99; p=0.040). Safety was also shown to be similar between finerenone and placebo groups, with renal adverse events (AEs) balanced between treatment groups and low discontinuation in the finerenone group as a result of hyperkalemia AEs.

    Additional data from the pre-specified pooled analysis FIDELITY were provided in an oral presentation, showing that irrespective of SGLT2i use at baseline, finerenone demonstrated consistent kidney and CV benefits versus placebo, and reduced UACR in patients with CKD and T2D (32% vs 37%, respectively).

    Preclinical data indicate that combination therapy with finerenone and an SGLT2i has benefits over respective monotherapy. In the prespecified pooled analysis FIDELITY, patients treated with an SGLT2i at baseline had higher mean eGFR, lower UACR and higher statin and GLP-1RA use. The new analysis shows consistent kidney and CV benefits of finerenone versus placebo, and an improvement of UACR in patients with CKD and T2D, irrespective of baseline treatment with an SGLT-2i.

    “Sadly, despite existing treatments, many patients with chronic kidney disease and type 2 diabetes are often still progressing to kidney failure or premature death. There is an urgent need for new treatments that can help to slow down the progression of disease in these vulnerable patients,” said Professor Peter Rossing, Head of Complications Research at Steno Diabetes Center Copenhagen. “Finerenone is different to existing treatments as it blocks mineralocorticoid receptor overactivation, a key driver of kidney disease progression. The analysis of FIDELITY underscores the potential role of finerenone alongside current treatment options to help ease patients’ disease burden.”

    bron:
    media.bayer.com/baynews/baynews.nsf/i...
  20. forum rang 7 LL 9 november 2021 07:52
    Q3 resultaten:

    * Bayer grows sales and earnings significantly
    * Group sales at €9.8 billion (Fx & p adj. + 14.3%)
    * EBITDA before special items increases to €2.1 billion (+ 16.4%)
    * Crop Science reports strong increase in sales and earnings
    * Pharmaceuticals and Consumer Health again post considerable sales growth
    * Core earnings per share at €1.05 (+ 29.6%)
    * Net income at €0.1 billion
    * Free cash flow remains strong at €2.0 billion
    * Revised outlook confirms good business performance

    bron:
    www.bayer.com/sites/default/files/202...
1.223 Posts
Pagina: «« 1 ... 49 50 51 52 53 ... 62 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,01 -0,62%
EUR/USD 1,0655 +0,11%
FTSE 100 7.895,85 +0,24%
Germany40^ 17.714,20 -0,69%
Gold spot 2.392,50 0,00%
NY-Nasdaq Composite 15.282,01 -2,05%

Stijgers

WDP
+3,12%
Kendrion
+2,92%
EBUSCO...
+2,67%
Vopak
+2,61%
NX FIL...
+2,17%

Dalers

JUST E...
-5,11%
TomTom
-4,68%
Fugro
-4,30%
ASMI
-4,00%
BESI
-3,64%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!